Last reviewed · How we verify

NCT05485870

Early Screening and Identification for Panvascular Diseases

Status unknown Last updated 3 August 2022
What this trial tests

trial in Panvascular Diseases in 1,000 participants. Status unknown.

Timeline
1 July 2022
Primary endpoint
31 July 2024
31 December 2024

Quick facts

Lead sponsorBeijing Tiantan Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment1,000
Start date1 July 2022
Primary completion31 July 2024
Estimated completion31 December 2024
Sites1 location across China

Conditions studied

Sponsor

Beijing Tiantan Hospital

Who can join

Eligibility, any sex, with Panvascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Identify the pathogenic factors involved in the occurrence and development of panvascular disease and its pathogenesis.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Circulating immune cell landscape and T-cell abnormalities in patients with moyamoya disease.
    Ge P, Tao C, Wang W, He Q, et al · · 2024 · cited 21× · PMID 38566524 · DOI 10.1002/ctm2.1647
  2. The intraoperative hemodynamic and clinical research of three direct bypasses in moyamoya disease a prospective cohort of 98 cases.
    Shi Z, Wu L, Li W, Wang J, et al · · 2025 · cited 1× · PMID 40830192 · DOI 10.1038/s41598-025-15654-w
  3. Unraveling the Dyslipidemic Landscape in Moyamoya Disease: OxLDL as a Key Biomarker.
    Zeng C, Chen H, Liu J, Bao Y, et al · · 2025 · PMID 40365738 · DOI 10.1111/cns.70441

Verify or expand the search:

Other recruiting trials for Panvascular Diseases

Currently open trials in the same condition.

Other Beijing Tiantan Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05485870.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing